Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BIIB104 in Healthy Japanese and Non-Japanese Participants
NCT04079101Phase 1Completed
- Sponsor
- Biogen
- Start
- Oct 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pesampator in schizophrenia (3 arms), sponsored by Biogen. Primary endpoints: Maximum Observed Concentration at Day 11, Time to Reach Maximum Observed Concentration at Day 11 and 7 more. Started Oct 2019; status: completed.
02
Drugs
pesampator
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04079101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04079101.